Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial

This study (n=252) reports that LDL cholesterol reduction was 31.1% with pitavastatin vs 20.9% with pravastatin (p<0.0001) at 12 weeks, with no statistically significant difference in virological failure or treatment emergent adverse effects between the two groups.

Pitavastatin is not currently marketed in the UK.

 

The European Society of Cardiology (ESC) guidelines on the management of dyslipidaemias (2016) states “Pravastatin is not significantly metabolised via the CYP isoenzyme system and is therefore a preferred statin in HIV-infected individuals. Preferred statins include atorvastatin, fluvastatin, pitavastatin and rosuvastatin, although caution should be exercised.”